RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

IntroductionImmune checkpoint inhibitors (ICI) have changed the treatment of non-small cell lung cancer (NSCLC). Furthermore, compared with monotherapy, ICI combination therapy had better efficacy and partly different mechanism. Therefore, we aim to investigate and improve biomarkers specialized for...

Full description

Bibliographic Details
Main Authors: Qian Wang, Tao Yu, Zi-Hao Ke, Fu-Feng Wang, Jia-Ni Yin, Yang Shao, Kai-Hua Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
RB1
non-small cell lung cancer
next-generation sequencing
cell cycle
chromosomal instability
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1172728/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1172728/full

Similar Items